RenaissanceRe Holdings Ltd. · RNR · FY2026 Q1 · Calendar Q2 2026
RenaissanceRe posts strong Q1 as underwriting and investments support returns
RenaissanceRe’s Q1 analysis supports the view that diversified underwriting, fee income and investment returns can sustain strong profitability. The case is tempered by softer rates, rising operating expenses, geopolitical exposure and possible investment volatility.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about RNR FY2026 Q1
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Relative to the prior-quarter analysis, the current quarter showed $591 million of operating income, a 22% annualized ROE, $353 million of share repurchases and $1 billion of new Property CAT limits. Management also reduced the gold hedge by half and emphasized private credit expansion, while maintaining its broader strategic direction.
Guidance delta
Maintained. Management plans continued capital deployment in U.S. catastrophe markets, disciplined repurchases, technology investment and selective portfolio growth; the operating expense ratio is expected to rise toward 5%–5.5% of premiums.
Key takeaways
- Q1 operating income was $591 million with a 22% annualized ROE, according to the supplied earnings analysis.
- Underwriting, fee income and investments remained the company’s three stated profit drivers; the overall adjusted combined ratio was 72%, while Casualty & Specialty was 99.4%.
- Management repurchased $353 million of shares and added $1 billion of Property CAT limits while highlighting adequate rates and U.S. mid-year renewal demand.
- The outlook remains constructive, but rate pressure, higher expenses, geopolitical losses and investment-market volatility remain material risks.
Management priorities
- Deploy additional capital into U.S. catastrophe markets and mid-year renewals.
- Continue disciplined share repurchases while maintaining liquidity.
- Invest in the REMS front-office system and talent.
- Expand private credit selectively and pursue aligned inorganic opportunities.
Follow RNR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 1, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Citigroup | Buy | Buy | Maintain | Oct 29, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Oct 12, 2026 |
| TD Cowen | Hold | Hold | Maintain | Oct 12, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Oct 9, 2026 |
| Keefe, Bruyette & Woods | Market Perform | Market Perform | Maintain | Jul 28, 2026 |
| UBS | Neutral | Neutral | Maintain | Jul 27, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Jul 23, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 23, 2026 |
| Mizuho | Neutral | Neutral | Maintain | Jul 9, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Jul 9, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 7, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 6, 2026 |
| JMP Securities | Market Perform | Market Perform | Maintain | Apr 24, 2025 |
| Jefferies | Hold | Hold | Maintain | Apr 11, 2025 |
| BMO Capital | Outperform | Outperform | Maintain | Feb 5, 2024 |
| Goldman Sachs | Buy | Neutral | Upgrade | Jan 8, 2021 |
| Deutsche Bank | Hold | Hold | Maintain | Oct 29, 2020 |
| Buckingham Research | Buy | Buy | Maintain | Jan 22, 2020 |
| Buckingham | Buy | Buy | Maintain | Jan 22, 2020 |
| Bank of America | Underperform | Neutral | Downgrade | Jan 16, 2019 |
| Keefe Bruyette & Woods | Outperform | Market Perform | Upgrade | Dec 10, 2018 |
| Nomura | Neutral | Reduce | Upgrade | Dec 7, 2015 |
| Sterne Agee CRT | Neutral | Neutral | Maintain | Sep 21, 2015 |
| RBC Capital | Sector Perform | Outperform | Downgrade | Feb 5, 2014 |
| Credit Suisse | Underperform | Neutral | Downgrade | Oct 18, 2013 |
| Bernstein | Market Perform | Outperform | Downgrade | Jul 9, 2013 |
| Janney Montgomery Scott | Neutral | Buy | Downgrade | Oct 9, 2012 |
| Janney Capital | Neutral | Buy | Downgrade | Oct 9, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $339.32. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Wells Fargo | Analyst unavailable | $319 | $331.38 | -6.0% | Oct 12, 2026 |
| RBC Capital | Rowland Mayor | $365 | $326.29 | +7.6% | Sep 22, 2026 |
| UBS | Analyst unavailable | $350 | $328.98 | +3.1% | Jul 27, 2026 |
| UBS | Analyst unavailable | $349 | $328.39 | +2.9% | Jul 27, 2026 |
| Evercore ISI | Analyst unavailable | $330 | $318.51 | -2.7% | Jul 23, 2026 |
| Evercore ISI | David Motemaden | $320 | $313.14 | -5.7% | Jul 10, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $354 | $322.37 | +4.3% | Jul 9, 2026 |
| Mizuho Securities | Analyst unavailable | $329 | $322.37 | -3.0% | Jul 9, 2026 |
| UBS | Analyst unavailable | $342 | $325.86 | +0.8% | Jul 8, 2026 |
| Wolfe Research | Analyst unavailable | $315 | $324.88 | -7.2% | Jul 7, 2026 |
| Morgan Stanley | Analyst unavailable | $320 | $326.29 | -5.7% | Jul 6, 2026 |
| UBS | Analyst unavailable | $326 | $301.07 | -3.9% | May 4, 2026 |
| Mizuho Securities | Yaron Kinar | $325 | $299.3 | -4.2% | May 4, 2026 |
| Barclays | Analyst unavailable | $328 | $310.61 | -3.3% | Apr 29, 2026 |
| Mizuho Securities | Yaron Kinar | $318 | $306.2 | -6.3% | Apr 13, 2026 |
| Evercore ISI | David Motemaden | $309 | $309.85 | -8.9% | Apr 9, 2026 |
| Cantor Fitzgerald | Ryan Tunis | $340 | $309.85 | +0.2% | Apr 9, 2026 |
| UBS | Analyst unavailable | $319 | $307.08 | -6.0% | Apr 8, 2026 |
| UBS | Brian Meredith | $312 | $295.26 | -8.1% | Feb 9, 2026 |
| Morgan Stanley | Analyst unavailable | $310 | $303.55 | -8.6% | Feb 6, 2026 |
| Mizuho Securities | Yaron Kinar | $313 | $305.29 | -7.8% | Feb 6, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $282 | $276.12 | -16.9% | Jan 14, 2026 |
| Mizuho Securities | Yaron Kinar | $277 | $270.1 | -18.4% | Jan 14, 2026 |
| Wells Fargo | Analyst unavailable | $281 | $274.72 | -17.2% | Jan 13, 2026 |
| Barclays | Analyst unavailable | $304 | $274.07 | -10.4% | Jan 8, 2026 |
| Goldman Sachs | Analyst unavailable | $267 | $274.07 | -21.3% | Jan 7, 2026 |
| Evercore ISI | David Motemaden | $283 | $272.64 | -16.6% | Jan 7, 2026 |
| Morgan Stanley | Analyst unavailable | $300 | $271.54 | -11.6% | Dec 16, 2025 |
| Mizuho Securities | Analyst unavailable | $281 | $271.54 | -17.2% | Dec 15, 2025 |
| BMO Capital | Michael Zaremski | $303 | $266.96 | -10.7% | Dec 5, 2025 |
| Morgan Stanley | Bob Huang | $290 | $265.6 | -14.5% | Nov 17, 2025 |
| Wells Fargo | Analyst unavailable | $285 | $247.56 | -16.0% | Oct 30, 2025 |
| Goldman Sachs | Robert Cox | $256 | $262.03 | -24.6% | Oct 14, 2025 |
| UBS | Analyst unavailable | $272 | $267.03 | -19.8% | Oct 8, 2025 |
| Barclays | Analyst unavailable | $278 | $267.03 | -18.1% | Oct 8, 2025 |
| Evercore ISI | Analyst unavailable | $244 | $253.93 | -28.1% | Oct 1, 2025 |
| Wells Fargo | Elyse Greenspan | $269 | $238.44 | -20.7% | Jul 10, 2025 |
| Morgan Stanley | Bob Huang | $285 | $248.1 | -16.0% | May 19, 2025 |
| Wells Fargo | Elyse Greenspan | $288 | $253.84 | -15.1% | Jan 14, 2025 |
| Bank of America Securities | Joshua Shanker | $391 | $273.82 | +15.2% | Oct 10, 2024 |
| Evercore ISI | David Motemaden | $229 | $261.47 | -32.5% | Oct 9, 2024 |
| CFRA | Cathy Seifert | $305 | $264.55 | -10.1% | Sep 23, 2024 |
| Barclays | Alex Scott | $287 | $259.04 | -15.4% | Sep 4, 2024 |
| Jefferies | Yaron Kinar | $270 | $226.94 | -20.4% | Jul 29, 2024 |
| Morgan Stanley | Bob Huang | $240 | $217.28 | -29.3% | Jul 10, 2024 |
| Wells Fargo | Analyst unavailable | $245 | $209.53 | -27.8% | Feb 2, 2023 |
| Wells Fargo | Analyst unavailable | $200 | $187.37 | -41.1% | Nov 29, 2022 |
| Morgan Stanley | Analyst unavailable | $195 | $183.69 | -42.5% | Nov 22, 2022 |
| Jefferies | Yaron Kinar | $162 | $150.66 | -52.3% | Jul 12, 2022 |
Track every rating change on RNR the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationRenaissanceRe Holdings Ltd., together with its subsidiaries, provides reinsurance and insurance products in the United States and internationally. The company operates through Property, and Casualty and Specialty segments. The Property segment writes property catastrophe excess of loss reinsurance contracts to insure insurance and reinsurance companies against natural and man-made catastrophes, including hurricanes, earthquakes, typhoons, and tsunamis, as well as winter storms, freezes, floods, fires, windstorms, tornadoes, explosions, and acts of terrorism; and other property class of products, such as proportional reinsurance, property per risk, property reinsurance, binding facilities, and regional U.S.…
Historical context
All RNR earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| CBOE Cboe Global Markets, Inc. | FY2026 Q3 · Calendar Q4 2026 | +5.8% | +6.8% | Cboe posts strong Q3 as options growth and new products advance |
| NWG NatWest Group plc | FY2026 Q3 · Calendar Q4 2026 | +2.0% | -9.0% | NatWest maintains guidance as Q3 growth and capital remain strong |
| ERIE Erie Indemnity Company | FY2026 Q3 · Calendar Q4 2026 | +2.1% | +5.3% | Erie pairs resilient demand initiatives with thin underwriting margins |
| COIN Coinbase Global, Inc. | FY2026 Q3 · Calendar Q4 2026 | +1189.2% | -10.6% | Coinbase offsets lower spot trading with prediction markets and AI agents |
| TPG TPG Inc. | FY2026 Q3 · Calendar Q4 2026 | +4.3% | +7.5% | TPG raises FRE margin outlook as capital formation accelerates |
| AJG Arthur J. Gallagher & Co. | FY2026 Q3 · Calendar Q4 2026 | +0.3% | +2.9% | AJG: Q3 growth and AssuredPartners synergies support outlook |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the RNR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-01T05:20:44.092002+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-01T05:20:44.089102+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-01. For educational purposes only; not investment advice.